Best of 2016: Our most wanted newsWhich European Biotechnology news stories topped the charts this year? The European Biotechnology team delved into archives and analysed the click statistics. And here they are: the most wanted news … more ➔
Blood test on the scent of prionsContaminated blood can transmit prion disease even if the donor does not yet show any symptoms. A new blood test could make the blood supply safer. Two reports show it can correctly diagnose Variant … more ➔
IMI launches €348m callElectronic submission systems of the Innovative Medicines Initiative (IMI) will open for biotech companies and research groups on 4 January 2017 to apply for collaborative projects with pharma partners … more ➔
Belgian spin-off Indigo challenges diabete... Indigo Diabetes NV has been spun-off from University of Ghent and international research institute imec with a series A financing of €7m. The companys needle-free glucose sensor addresses … more ➔
EMA recommends market approval of four bio... The Europan Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended four biologics, among them three biosimilars, one monoclonal antibody as well as two targeted … more ➔
Evotec bags US$45m upfront in Celgene dealNeurology specialist Celgene has nailed down access to Evotecs induced pluripotent stem cell (iPSC) platform for screening of compounds against neurodegenerative diseases. more ➔
Grifols confirms €1.75bn acquisition in...Spanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit. more ➔
Oncology: Orion teams up with Wi2 Finnish theranostics specialist Orion Corporation is set to fill its oncology pipeline through a drug development alliance. more ➔
Curetis bags EIB debt financing and expand... Dutch-German molecular diagostics specialist Curetis has bagged debt finanancing from the European Investment Bank (EIB) to expand its automated multiplex PCR platform Univero. The company will receive … more ➔
Crenezumab data support Amyloid-beta targe... While competitor Eli Lilly has abandoned commercialisation of its Alzheimer’s therapy solanezumab due to lack of efficacy in a pivotal Phase III study, Genentech has tabled data supporting further … more ➔
